Vermillion scoops up bankrupt Correlogic to help develop next-gen ovarian cancer test
This article was originally published in Clinica
Executive Summary
Vermillion has acquired the assets of bankrupt fellow ovarian cancer diagnostics specialist Correlogic Systems for $435,000 in cash. The purchase will help Vermillion expand its ovarian cancer diagnostic portfolio, which includes the next-generation OVA2 test.